0001493152-23-040786.txt : 20231114 0001493152-23-040786.hdr.sgml : 20231114 20231114083035 ACCESSION NUMBER: 0001493152-23-040786 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231114 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RenovoRx, Inc. CENTRAL INDEX KEY: 0001574094 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271448452 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40738 FILM NUMBER: 231401761 BUSINESS ADDRESS: STREET 1: 333 W. SANTA CLARA STREET, SUITE 900 CITY: SAN JOSE STATE: CA ZIP: 95110 BUSINESS PHONE: 408-800-2649 MAIL ADDRESS: STREET 1: 333 W. SANTA CLARA STREET, SUITE 900 CITY: SAN JOSE STATE: CA ZIP: 95110 8-K 1 form8-k.htm
false 0001574094 0001574094 2023-11-14 2023-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2023

 

 

 

RENOVORX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40738   27-1448452

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

4546 El Camino Real, Suite B1

Los Altos, CA

   94022
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 284-4433

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   RNXT   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 14, 2023, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release of RenovoRx, Inc., dated November 14, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RENOVORX, INC.
Date: November 14, 2023    
     
  By: /s/ Shaun R. Bagai
  Name: Shaun R. Bagai
  Title: Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

 

Collaboration with Imugene further validates TAMPTM (Trans-Arterial Micro-Perfusion) and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy.

 

The TAMP therapy platform is in a Phase III clinical trial for the treatment of Pancreatic Cancer, interim analysis was completed in March 2023, and the Data Monitoring Committee recommended a continuation of the study.

 

TIGeR-PaC is prespecified to provide a primary endpoint of a 6-month Overall Survival (OS) benefit and secondary endpoints including reduced adverse events versus standard of care.

 

Los Altos, CA, November 14, 2023 - RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.

 

“We remain focused on our core mission to improve the lives of patients diagnosed with difficult-to-treat cancers by delivering novel targeted combination therapies that have the potential to alter the current paradigm of oncology care,” said Shaun Bagai, CEO of RenovoRx. “We are encouraged by the progress in our pivotal Phase III TIGeR-PaC study, and the recent completed interim analysis, along with our partnership with Imugene as we explore pipeline expansion opportunities using our TAMP therapy platform.”

 

Key Business Highlights:

 

  ● Continued to advance Phase III TIGeR-PaC clinical trial for the treatment of LAPC. The first of two interim analyses was completed in March 2023, and the Data Monitoring Committee recommended a continuation of the study. The study is prespecified to provide a primary endpoint of a 6-month OS benefit and secondary endpoints including reduced adverse events versus standard of care. Additionally, Dr. Michael J. Pishvaian, Johns Hopkins Medicine and Principal Investigator of TIGeR-PaC, presented at the Global Summit on Gastrointestinal Malignancies in Bermuda. The presentation, “Increasing Local Gemcitabine Delivery Using TAMP in the Chemotherapy Advances in Pancreatic Cancer,” highlighted the proprietary TAMP therapy platform and its design to ensure precise delivery for targeted treatment of cancer, and its potential for increased safety, tolerance, and improved efficacy.
  ● Ripal Gandhi, FSIR, FSVM, investigator in the TIGeR-PaC study, presented, “Advances in Pancreatic Cancer: Trans-arterial Therapy on the Horizon,” at the Symposium on Clinical Interventional Oncology (CIO) on September 22-24, 2023, in Orlando, Florida. Dr. Gandhi highlighted the TAMP therapy platform as a potential targeted treatment option for patients diagnosed with locally advanced pancreatic cancer versus the standard of care. Dr. Gandhi is a member of the Miami Cancer Institute and Miami Cardiac and Vascular Institute physician team, a Clinical Professor at Florida International University Herbert Wertheim College of Medicine and Associate Professor at USF School of Medicine.
  ● Collaboration with Imugene Ltd (ASX: IMU) further validates the TAMP platform and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy.

 

 

 

 

Financial Highlights for Third Quarter ended September 30, 2023:

 

  ● Cash Position: Cash and cash equivalents as of September 30, 2023, were $3.2 million.
  ● R&D Expenses: Research and development expenses were $1.6 million for the quarter ended September 30, 2023, compared to $0.8 million for the quarter ended September 30, 2022. The increase was primarily due to our ongoing Phase III clinical trial cost of $0.4 million, an increase in employee and related benefits costs of $0.3 million and general and administrative allocated costs of $0.2 million. This increase was partially offset by a decrease in costs associated with a secondary manufacturer of $0.1 million.
  ● G&A Expenses: General and administrative expenses were $1.3 million for the third quarter ended September 30, 2023, flat compared to the same period last year. Employee and related benefits costs increased $0.3 million compared to the same quarter last year. This increase was offset by a decrease in directors’ and officers’ insurance expenses of $0.1 million, including allocation of general and administrative expenses to research and development of $0.2 million.
  ● Net Loss: Net loss was $1.4 million for the quarter ended September 30, 2023, compared to net loss of $2.1 million for the quarter ended September 30, 2022. The decrease is primarily due to an increase in operating expenses of $0.8 million, offset by $1.5 million reported gain on the fair value of common warrants issued under our Registered Direct Offering in April 2023.
  ● Shares Outstanding: Shares of common stock outstanding, as of September 30, 2023, were 10,693,080.

 

About RenovoRx, Inc.

 

RenovoRx is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic (intravenous (IV) therapy). RenovoRx’s unique approach is under investigation for targeted treatment with the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGemTM, a novel oncology drug-device combination product, is being investigated under a US IND that is regulated by FDA 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA.)

 

RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.

 

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath®, RenovoGemTM or TAMPTM or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, statements regarding the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and our preliminary financial results, cash position and related ability to continue as a going concern. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, clinical trials, therapy platform, business plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; the possibility that interim results may not be predictive of the outcome of our clinical trial, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, or the regulatory authority may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; our ability to use and expand our therapy platform to build a pipeline of product candidates; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercialization potential of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; negative impacts of the ongoing COVID-19 pandemic on our operations; our ability to comply with the continued listing standards of Nasdaq Stock Market LLC (“Nasdaq”) or the continued listing of our securities on Nasdaq; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

 

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

 

 
 

 

RenovoRx, Inc.

Selected Condensed Balance Sheet Data

(Unaudited)

(in thousands)

 

   September 30, 2023   December 31, 2022 
         
Cash, cash equivalents and marketable securities  $3,226   $6,440 
Total assets  $3,519   $7,265 
           
Current liabilities  $1,605   $1,102 
Common warrant liability   1,908    - 
Total liabilities  $3,513   $1,102 
Total stockholders’ equity  $6   $6,163 
Total liabilities and stockholders’ equity  $3,519   $7,265 

 

 

 

 

RenovoRx, Inc.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Operating expenses:                    
Research and development  $1,629   $846   $4,892   $3,525 
General and administrative   1,354    1,315    4,727    4,255 
Total operating expenses   2,983    2,161    9,619    7,780 
Loss from operations   (2,983)   (2,161)   (9,619)   (7,780)
Other income/(expenses), net:                    
Interest and dividend income   43    22    97    43 
Other income, net   -    3    -    4 
Change in fair value of common warrant liability   1,519    -    3,092    - 
Transaction costs allocated to common warrant liability   -    -    (575)   - 
Total other income/(expenses), net   1,562    25    2,614    47 
Net loss   (1,421)   (2,136)   (7,005)   (7,733)
Other comprehensive loss:                    
Unrealized gain on marketable securities   -    17    -    13 
Comprehensive loss  $(1,421)  $(2,119)  $(7,005)  $(7,720)
Net loss per share, basic and diluted  $(0.13)  $(0.24)  $(0.69)  $(0.86)
                     
Weighted-average shares of common stock outstanding, basic and diluted   10,693,080    9,067,509    10,154,914    9,039,308 

 

Investor Contact:

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T:212-896-1254

renovorx@kcsa.com

 

Media Contact:

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !' 4H# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MI,C.,C.,XSSCU^GO2Y'K0 449'K10 449'K10 44F1ZCIGJ.GK]/>ER/6@ H MHR/444 %%'].M)D#J0/Q'^>QH 6BBB@ HHR.>1QU]OK^8HH **** "BBC(]: M "BC(]?;\1U'X8-% !1110 4444 %%%% !16%J_BGPSH$D<.N^(]"T26:)IH MHM7U?3]-DEA5BK31I>7$+/$K JTB@H&!!((-;@(8!E(((R""""#T((X(/J*N M4)QC"U)D>H].O?TH M6BC(]:* "BBB@ I#T/T/7@?B>U+2,<*Q]%)_2IG+DA.?\L)2_P# 8RE_[:!^ M>WQM_P""KO\ P3E_9P^*?BSX)_'7]L#X+_"SXK>!7T6+Q=X%\8>)!IFO:&_B M3PSHOC+0EO;62W(4:GX9\1Z+K%JT] M:QN9$(BNUM+O3'M;DQ.1)Y-PABDP5<88Y_HO,_#[P?X4R?@+&\8\1^(5''<: M<'Y9Q3RY'D>0XO!818R=7#XF%.IBL93KU*>%Q-)QA"<(U:M.+E%IR@E\W2S+ M.,7B,RIX/"8*5' 8VK@^>MB:D*E25.$):05*25U4BG[RBGUW9_0?\,OBS\,? MC-X9M/&GPE^(/@WXE>$K](WM?$7@CQ'I/B71W$D2R1I]MTFZNHTE:,AC#*R2 MJ/O(N#7H9P/;KSCGW/Y\\@C\Z_S._P!H3X5?M_@77?@M\4==\8?L M]?$R.3Q;X;ANU:Q\.?&/P)H.K6MMXY^&_P 2?"EM(NA1_$+PK;ZA920>(M(A MMYY(M9T;6;&6S:YN]/A_T;_@A\7?"OQ\^#WPQ^-G@:X^T^$OBGX&\->/- 9G M5Y(M/\1Z5;ZBEI<.GRF[L'N&LKP+\HN;>95X S\-XB>&T.#<'P[Q)DF>4>)^ M">+Z6+J\/9Y##SP6*<\'.,<5E^:8&:MA5YO M]?J8O"5Z$L'F&!E%8G#2E[1*,U>G4IU%[LX3Z6;M=.[3T\Q_:5_;9_9-_8Y@ M\(W'[47Q^^&GP,@\>SZO;>#9/B)X@@T)/$<^@QVW-?SQ_\'D.1X9_8 M(D7@IXI^/)7(#88^'/!(R1Z8)!QDC(QT)KLOV0?^#8/]B;]H']E_X _&[Q1\ M5?C_ *=XD^*'PM\)>-MWEK812:/++'9Q2RE+=9)9) M%106;+$+]KE/AIX8X3PNX7\0N.>*N,68/!Y#DN6YGA>?)JZA/GJ M5Z]'$47.BW43J*<'*+C%*UWPXC-\SGFN,RS+L%AL1+"4:-:I*OB94+PK:*WN M23:DK6T=M5=:'[\Z7_P6F_X)0Z[JFF:+I'[?7[-6H:KK-_9:3I5A:?$/3Y+J M^U+4KF.SL+*VC"@R3W-U-'!$@!W/(J@?-7Z>AU=0P(97&5(P05*[E;([,!N! M]Q7\O/A+_@U'_85\'^*_#'B[3_BY^T-/J'A3Q%HOB.PANM?\/-;2W6AZE:ZG M;PW"IHRL]O+-:1),H(&%J585:M@*N95(U7F.%P^%FFO9^PQ'MXSC9\SDU"#BXZ:-:ZV>QQD/Q)\!W' MQ)U+X/P^*]%;XG:/X'T3XDW_ ((-Y$/$,'@3Q'KWB+POI'BL6#,LTVC77B#P MKKFDO>0+)';7UF(;IH6NK3SNZZU_"]_P<6_M4?&3]B__ (*__LB?M#? KQ'/ MX>\<^"_V0=">2$M(^C^*/#L_QR^+IUWP=XEL494U/P]XBM8_LNH6LN3&R6][ M:F*]M;>9/ZI_^"\BN->^ M&WCF*V1[_1-2C4^;+IMT0U[X=UCRQ;:OI;QRQM]HBNX8?1S[PTSW)N!.#_$: M$?KO#?%.'K4ZF(I1M+*LVP^*Q6'G@L7%-R]CB*5"G7PN*Y52&[CQ1;:[\*_#WB>TO_&6DW'@ MJ[2R\5PWND1CSH)- NY%M]25CF"5MK9-?7F&CAW'%XA9IA\![#$NO[T<.J=:51RP_[WGC%?"PS+,9X'$931C2C468X M_P"IRDVTZ2]A4JJ<;;N\&K/2WR/[X@, #T ';^F/Y >E5+_4+'2[*YU+4KVT MT[3[.%[B\OK^XAM+.TMT&YY[FYN)(X8(D R\DLB(O5F %9/BWQ9X>\"^%O$? MC;Q=JUEH'A7PCH6K>)O$NN:C,EMI^CZ#H>GSZGJNI7MQ(52*UL;&UGN9Y&(" M1Q,3VS_GY_M-_ML_MN_\%Y/VLQ^R_P#LDR^(/"/[/::E>?\ "-^$8-1OO#FA M2>!M,N?LUY\7_CIJVGE;FXM;Y#'<:3X5\QXH!'^&.&<-2QG$_%&:\ZR_*,J=3$XO&U?J^!P=&+=3$5FKI.235*G':52:44]+IIM?V M,?$+_@K9_P $U?A7KL_A;QS^VE\ ](\06LSPWFE1^.=/U6ZM7C95D-R-):\C MA6-F =WD"+M?)^1\?0_P/_:]_9=_:6M_M?P"^/GPJ^+2"-9&A\$^,]&UB^2- MAN+R:=!=#4$4*"26MP%VG."#7\Z_P5_X-3?V8O#?A*S@^-7QR^*OC;QE+;(^ MHR>!H]'\$^%;'4"7,O\ 9%F;._U.XM1E0O\ :5T7]EKX3_ &WO^#=W MXV?L:Z+J/[3W[!?QB\>>.C\.()O$^M>&$D;PS\:M$TK38WN[S6O!GB3PLUFG MBB/1X%>XNO#\]O#>7-E#,T"WCJT#_H&'X%\ LZQ4,@R7Q6XEPN=U*KPV#S;/ M>&,/A^%,4X3G"*;FH^"]._M?Q7XN\0W'V/1=!TSSXK8WVI7 M>UQ;VR3SPI),RE$W@OA,MEOIW_"YO &G7%IIVIW][IZ"&&#X@>$YKS3F\1P6*>5KFE7\7B" MUMH?L6M>1_0C\0_ 7ASXH^ _&7PW\96*:GX5\>>&-;\(^(;%PI%SH^OZ=7UJ.(A M7R^O+#U5CLKKR7L<1"O@:LZV&G444JD'0KPA.%1+Z# 9CALTP4<;@IJI":J1 MC&2<)0K4^92I58O6,H32B^CC*,XN49)GE?[//[6?[-7[66D>)-?_ &:_C;\/ M?C7HO@[5+31/%&H?#_Q!:Z];Z%JU_9#4;&QU)K?YK>6\L6^TVWF +/$C-&S& M.3'T.,\?KQ]<]#@<_7OZY'\%_P#P2:\?^*/^"7/_ 6 ^)7[&WQ4OI]/\"_% M3Q'=?L^ZRUT9H+ ^*8;ZZ\4?L\_$2W281-+INOZ=?_\ "+6]_+%$#I_Q L+Z MY,<&GD+_ 'F[@3MXSUP>W3 ]3\W7V]J]SQ2X#AX?9_@L'@L?+-LAS[(LIXEX MSDDHSBR> ?'O@[XI>#/#7Q$^'WB+3?%O@CQEI-IKWA7Q-H\QN-)UW1;Y/-LM4TZX* MIY]G=Q8EMYP/+FB*R1ED=6;^%W]MWQ)JO_!7'_@M-X1_9P\(:K-=_"SP9XSA M^"5I?:6YEM[/X>Y\5?''QM"\86'?J$\7BBQTC4]IDN)&T&U>26WLH57^ M[?P_H6C>%=!T7POXE:/I%E!IVEZ=9Q D1VMA M8VT%M!&#\D<2KVK?Q!X"P? 61\ 5,3F.)K<4\59!4XDSO*9PH0PN1X'$XMT\ MGP\6DL4\7B,+>MB?K"4824O9+DA.RRO-WFF)S.-&FEA,OQ?U&G7][FKXFG&^ M)23]UPI2<8J4;IN:5[W-K\?7_/X5\F?&/]NO]CK]GZ_;2_C-^TI\'_A_JJL5 M;1]=\::.FL*PQ\CZ9;SW%['(00-DD".02 ,CC^=3_@M-_P %:?BW+\6[S]@3 M]BW5=>T_Q.FJ:;X'^*/CCP,L\OCOQ#X]\375KI>G_"#X<368>\T^\AO-0L[# MQ1JUF(]5FOKJ32=*DMDL[F\N*_[*?_!M3'X@\.6'CW]L[XN^)++X@^(X8M6U M;P%\/;BRO;K1Y+W-Q-8>*?B%JT>H7?B#7(VD(O[C3X_L<5UYJ6]Y=1J)7^GR M?PGX%Q3I83+L!55 M6G*%?$S4G"I3DVY3A1?!BL^QE?&503]E*Z.%9&#JZAE=2&5D895U8$J58 M8(89# @C(P:_E8_:+_X-F?A[<>&[[6?V7/C/XHT;QQI=M/=:'X;^*?V;6-!U M"]@B\V"UA\4:5;V6N>';NZF1(HM52.]ALF82/;%-S#P+_@EU_P %-_VA/V3? MVA(_V#_VY+CQ(_AZ+Q7!\-].O/'UY+?>*_@UXPE=(M'L9=?N&FG\3?#K7S+FJ-#&X6JZV!J8B2O&BW)>TISG:5N=1BK6;:=U_9,.@YS[_ ,OTI::A#*&! M!#?,"""""<@@C@@@Y!'!'(IU?@J=TGWUVM\K:6:V:MNF?3GY._\ !0]$?Q?X M0+(C$>!M6P64$@?;K_ID'_)-?JU:?\>EK_U[P_\ HM:_*C_@H;_R-WA#_L1M M6_\ 2^_K]5[3_CTM?^O>'_T6M?:\1?\ ),\"^>69A\_^%'%;Z:_C\CS,'_ON M9_\ 7^G_ .FH$6H7MGIEC>ZEJ%Q'9V&GVEQ>WEU*P2&VL[."2XN;B9B,"*&% M)))"=RA$+8X-?G[!_P %8_\ @G!<01SP?MC?!*:*95>*1/%43"5&42+(A,6# M'(CJT; ;"K J67%?;/Q'/_%O?'AYP?!GBG('#'_B0WIX]#V],FOX7?\ @BW^ MQC\$?VVOB5\0? WQUM/%%_H?@[X-^'_%FBKX9\1W/ARZ75[G6M!TAYKJ[@AG M>YB-G=3HMNX\L,V_&Y5Q]=X::S;>'O"O[6 M/P3U76;V00VNGKXUTVTEN)G&46-KU[:-BPSMR^"V!PV /MBQOK/4;.WU#3KN MVU"PNH4GM+VRN(;JTNH)%!2:WN8'DAFB9%PN.JO#8;&8'&U<5&.(MSJ&(IUJ M%)TX3BTHS3;4GLX\UOZY_&OC/PK\.O"/B/QWXWURP\,>#_".CWWB#Q+XAU20 MPZ;HFBZ9 UUJ&J7\RJ_DV=E;H]QZWUE8ZE97FG:C:VM]IU_:SV%_8WD$=S:WMG=1/;W5I=VTRO%<6US \D,T,J M/%-$[HZLA(/\8<$6N?\ !'3_ (*GS6Z?;;;X">-=0EDTWQDN';%[J7PLURW.DO+R*RWZRS_ "?AWP+A/$##<59=AKRU:6,H86,L104:O+5A.*47*$XR]/-\UGE4 ML!5G2C+ U\4L/C<0W+FPOM(I4)\L5[T957RR;34;=+IG]E'BGQ5X<\#^&M>\ M8^,-;TSPWX5\+:1?Z[XBU_5[J.RTO1]'TNVDN]1U&_NIBL<%K:6T4DTLC' 5 M>,D@5XQ\#_VL?V;OVD[K7K+X"_&?P)\6+GPO;65[XAC\%ZU'K(T>VU*:YM]/ MDOWA41VXO);.Z6W1F#2""1U4J"U?AQ_P7E_;1L['X9^#OV4OAKK0U"_^+]GH MOCCQ]=:'*UQ-/X":>&^\&^'[<6[>9+_PF>KQVFH;(U\V>TLM/B020ZB\3_IE M_P $N/V04_8^_96\)>&=>L8X/BM\0DB^(GQ:G*)Y]IXCUNVBDTSPAYH16:U\ M!Z$]EX:50S0RZG;:OJ4.U=2*C;%\ X+)O##+>.L_S#$X;.>*,YKX#A#AZC"@ MI8C+>)SS$97AJ,9X? X>%7& MXMR=J=>O[U'#TXK2E46UZ=17[7IU%?Y7O\AK=>J_-'^=9^V&"W_!WAH2J-S']L?]AW:.#D_\ M,J_LWC'KQ@X&>1VK_1..?F/0?WB#G )S_#P .0.<\8 R17^91_P5\^&_Q1^, M/_!R=\:/A3\$?%Y^'_Q@^(GQO_9&\)_#7QU_:5]HQ\(^,]5_9#_9QBT77DUC M2P^I::UA/ME%W81M=1L((H]! MUJZ3P]9?M"_%^WOO$UU:Z?RP]Z=IIM MR25]-TU9:H\Y_P"#LO\ :]^%WQR^.W[.G[(/PAU'3_B!X]^ 3^,=9^)]YX;E MBU?^P?'GQ,'AK1?"OPMM[BT:5)/%4-CHLFJ^)M'C,[V#:QX:M+H07ZW=M'_9 M9_P36^"?B?\ 9S_8'_9+^"?C42)XM^'GP.\%:-XCMYBWGV6L3:>-3OM.N P4 MBXTV>^>PG7;A)K9U4D $_P +?_!K_P#"']D?X@?MV^/O#W[4'A#4]0_:B^'% MC/XU^ >@>-KB5= B\9^$=7U6T^*PUWPW?PBZU#XJ^$[[[+JVG_VK(XM5L/$M MW(RW@B@L^K9Y MBZ=.%+B#-.)L+#&ULQRI4W.V55'B<1[#][-+EIT'>IAZU6MT\-%?V#% RS>*? MCRJ@$ EF\/>!P.O'4\YR,=?2OM;]B#_@X)_X)9?!/]D']FOX0_$'X\^(],\= M?#WX.>"?"OBO2H/A)\3-133]>TC2(+74+(7]AX7EL+SR)XV43V4TUM(NUHI2 M"0/BC_@\@9D\*_L%N.J>*OCPP]*=0B^)_C6SAOMZ_T M/_UJ_F3C2? DLSHKP^7$?]C+!T5B'Q1/!3S"68^UE[65)8&4Z,,,J?)[.+E* M?.I2?8^MR]9FJ#6:RP;H>MRQ8&I)IVO10R:)JFIV@]]_P"# MJ'/_ ]%_8\P2/\ C''X99.2!_R&KF92(-4TFX?=)"Q6 MWU*Q>YTR[S;74FW^IJ/B+2X'\-/ ?*,]P<'J0A.+E2K/G52ZMS2B]8*<7U'[)?[5_P %?VU_@1X& M_:)^ ?BB+Q-X!\:V9)BE"6^O>$_$-GLC\0>"/&6D"22;0/%_AB^#_ ,S!^V;Q_P!S?I9!';ICW],5 M\P_LT?';]JW_ (-TO^"@GBKX$_&FQU'Q%\"_&^J:5>_$30;".Y/A7XK_ \N MKUM)\,_'[X4-=,L-MXJ\/V,4MCJMN72X=M/O_!7B4+-::3=P>[_\$4_&OA?X ME?\ !P9\;/B-X(U3^VO!GCZ+]K'Q?X1UGR)K8:GX=\0>(-#U+2;[[-.JS6YN M+.XCD,,RK+&24;D$EY=X7U> WI4M:N=T\QQ?#F%Q$7ALVPF>^ MSQ>"FTI6A@JT7B*:L_W-22TCJX3FXN32C*7](W_!Q/\ $[Q!\-/^"4GQ[/AV MYN;.X^(6N_#'X4ZE=VLDT%Q#X?\ '/CS2--\0*LD+*PBO=)CN=.ND;='-97E MQ#(I23CXM_X-5_@GX2\-?L@?%WXZ0V=O-X\^*/QBU;PGJ.L&.-KNV\*?#ZSM M(-$T>&4@S6UK)=ZI>ZA,/#NG)(Q58I-9NM(.B),Q"P'41*W" MD5_+M_P;3?\ !0SP7^S[XK^)7["O[0>K1?#K_A/_ !M/XF^&>J>+I$T2TTWX MHPK_ &#XU^&VO2WS00Z+J^HW.G12Z9'>&"-]3LKC2QLN)X1+\+PA2Q6>?1IX M]R#AUUL3G6!X[RW/L]RC J=7&XSAVA@JU"."22R\-^&--:5+ MG6_$>K3(+73M,LU>621C-,8;2&XN(OYKPN%Q&/Q.'P.!PU7%XW%UJ6'PN&PU M.=:O7KUYPIT:5.E!2J.$_VC8](TOQ'X7B@M]JPZ1IUO\1]3CMM.15M8;>RLH_)9;917^A@> MOY8'!.X-@$XZ Y'OC.<8K_/H_P""7'@SX@_\%0_^"SFK_M<:[H-S8>"O 7Q, MO/VFOB%=+&\VF>&_L)GM?@I\/'NY66*35)=4M=!%I#"_GW&F>#_$.IK$8;9R M?]!D Y]>OOUZ_G_ "K^COI+1IX3,_#;(,35HUN*N'?#/(LOXSJ0Y9U89W.< MJ]/#8NLIU'6Q.%P4:5&JYS;5I-6C5CS_ !G!,IU\-G&+A3=/ 8O.\95RQ/13 MPB?+[:$;1Y:=:;_V5+WPIXR^ O[>_P /;5M-O[R[TWX, M_$O5K!%AFLO$^@'4?%_P<\4SRQN)?M-Q;VOB?PK=WTD>Q/[-\)6+3JPMH9?T MX^(7_!6+2$_X(Q6/[:6D:M;)\6_&GP\A^%5CI\,D?VS3_P!H6YAE\(>(52W6 M6":*32]0M]0\8V"+&[I8-I4\UL8;@J/U)_;<_9E\.?MB?LI_&_\ 9Q\2!8H? MB5X)OK#0M3,:R2^'_&NE20:_X#\36ZMUG\.^,=*T35U0G9<):/:S!X)Y8W_S M,?#=G^T5XPO?#'[!"W.LPW#?M$W&F6GPK(G>QT;XV:I>4J5*G>,84W537FY]B:_#6:8S%86+='B+".A3I4 M[Q]GG*:I1Q*;O&]2-6+<8Q4YR;=W9M?U2_\ !L1^R+)8>$_C+^W+XUL6FU[Q MY?ZE\&OA1>7BEKG_ (171=8CUKXH>*5>4$2-XK\;0Z9HUI=QB-DM_"&J2133 MV>N%8_ZH/B!KMQX6\!^-O$UDJO=^'/"/B37[02()$:YTC1;[4+=&CQ\Z&6V7 M5Y1A<%>+Q$*+GB*J7\3&UX\ M]>K*[;;=9Q4FY-VI)-WU/X3_ /@WO^'VE?'W_@I9\0OC1\1Q'K7B/X7> /B% M\8]%CN_W\07+2//>:!X7USQ7::?O+FUFUNWOD,=WI]E+' M_> I .!C.2",=!U^H['GJ22_X*W>(]$^+.G:A!\-5U M#Q;\./&UQ;6MPO\ :WP/^(^HZ;K_ (,^)N@1O'(VJQ>&-2T;2]>D@M4DN[K2 M[;Q1X>MT76"D4']\W@_QCX5\?^%]"\:^"/$&D>+/"7B;3;?5] \2:#?6^IZ1 MK&FW:F2"[L+ZU>2">)N0V'W1R+)%*J2QNB_J_P!**CF&/XUR?BVC[?$\'<0\ M)<.PX/S"G%SRV."P.5X:G7RS#5Z_R24).EX?!$L/1P M&+RY.4,?AW3 MZD9]!7\:/_!S3\*_#OA7XS?L\_&WP]$VE^,?'W@KQ;X9\07MILA>]N?A_=Z7 MJ7A#6I=FUY=2T==9O((+F3I74%AI^GV-K&\UU>WM[=/%;6EK;Q(\]Q<3R1PPQQF61U12P_A/_ ."I MG[1<_P#P5/\ V]/AI\ _V:S<>+_!/A.\7X2> ->L(I)[3Q3XC\1ZG$WQ \=V M4;1K+!X7T6ULS;VNJ3I'%>66CS:AD6ES:L_']%_#8VEXH4.()TJD>%^'\FS_ M !7&.*J7A@%D-?*,1A\1@\16G#ZO*IB)SHU:.'E.4Y/"RJ*GRQ4WIQM4I?V) M/#)J6/Q6(PM++*<6O;2QKJKV6^G\/6*W,[LY9B\\J-,Y9B2SDDU]*5YS\ M'_AYIWPD^%7PY^%^D$'3?A]X+\-^#[1USB6/0-)M=-,P! (\][=IL$9&_!YK MT:OP?,ZF&K9GF57!+EP=7,6V%J8[&3PRY79Q_<3HV5E9-*RL?5X>, MXX>A&I_$C0HQJ:W_ 'D:5)3UZ^^I:]=S\G_^"AG_ "-WA#_L1]7_ /3AJ%?J MQ:?\>EK_ ->\/_HM:_*?_@H9_P C=X0_[$?5_P#TX:A7ZL6G_'I:_P#7O#_Z M+6OI^(O^29X$_P"Q7C__ %88HXL'_ON9_P#7^G_Z9IG(?$;_ ))]X[Q_T)OB MKG_N!7W)Q@/.@_P"*,\4#@#DC0K_G\,]/?':O\_+_ ()F?LX_M0?M)^*? M%7AO]ECXO2?![Q7X<^%^@ZWXGU:'Q/KOA9]:\/3ZCHUC#I1N]"C>:X6+4I(+ MW[/<@0*8 P/F[ ?VGP2RG YUX1^.V5YCGF!X<*E2A3P\53O+VN(I?84FOF.)JU;#Y_PM6P^&GC*T)8]PPU.<:< MZTI4^648SFG"/+&4IMM6:@UN[K_0MUG6='\.:5J.N^(-5TW0M"TBRNM1U;6= M9OK72]*TO3[.![B\O]0U&]>WM+*SM;>*2>YNKF5(884>21PBL1_$7KGB>#_@ MH3_P6<@\7?!6VN;OP?K?QF\"SZ%K]I;SQI/\/_@EX7\.Z1J7Q#O1.L.?$-OI^G:M>C3[;Q7K&DZB\&F7FBZ-JTNFV]]YT M4\M@-174_P!U:6=Y-%^O7_! CP-^S7_PS1J'Q0^'>BM_PORYU;4O!OQMUK6K MB&]UNR>RU.6[T+3?#L8R^C>!M6TR"RO[*V0 W^K66H&YGNCIUOY/L<.97D/@ MOP;Q?XC9#Q?EGB%FN<8/'>'653X?PV(HX#(ZF?83GQ^8YW0S*,\1["6&A&AA MFXJ$\6Z5&B^>52O#GQE?'\0YKA,DQ. EE6%PKI9M7G7JQJU<7&C4484<.Z4( M1C*,DY.2E+W7-R248QE^^.TDGJ 3G'Y]P2.0>O.,$8YK\9?^"WW[+'A[XZ?L MD:K\4UGTW2O'W[.S7GC?0M7OY[:RCU+PM?"VM/&O@ZZN[AXHV@UFSCM-0TV" M20JGB#2=*FCBED7RY/VV>X]<^G?/IDU_,'_ ,%[_P!JW5?$&K_#[]A# MX737&I:WX@OO#OBWXJV&EEYKB]N]6O8;;X9?#V1(2)?/U._EB\5:G;;'62S7 M0%=7@N[A5_&/!+*,\S7Q.X5I\/5OJ>+P&+J9OC,=44I8? Y+EN'KXC.:^+CS MTE4PT\O5?#3HSJ0C7GB:=*_,E;Z#BG$8:ADF.^LT_;?6(+#8>@I*,Z^+K37U M:%-V=IQJQ]KSJ,G&%*3>C/@;_@CI^S[_ ,-;?MAZ9XY^*WB$^*O#_P"SKX:\ M/>-/['\0ZFM]JNO:KI=V-)^&>D)9WDTMW-X7\+7%D-7G3'V*UN-,T;3VCDCO M95C_ +=$.1^)YSGICKP.?7KR.., ?PUMX(^,'_!&3]LGX"^/O%-U=ZQX>UOP MCH&K>,Y=-A:&RU[P=XG6WL?BEX-*!G2ZU/P;J*P7E@ 0]S>:987<0,;[6_MY M\+^)-$\9>'/#_B[PSJ5MK/AOQ5H>E>)/#VKV4BS6>JZ'KMC;ZII6HVDR92:U MOK"ZM[F"5&97CD5@2"*_2/I.3K9QQ+PYQCEF-P^8<#<09*\/PG6P&'EAL#@Z MF68BO2SC >R;Y:>+JXI1S*I"]*,:2=7R.!FJ&#QF7XBG*EFN%Q7/ MF"JM.K45:,98>=]W3IT_W"LY04DVI>\^7>HHHK^:#[D*1N0?H?Y4M%*2YHRB M]I1E%^DDXO\ !L#^'O\ :7_X)X_MN^+_ /@YOT3]KOPQ^S1\2=:_9EM/VHOV M1?&-U\:;.#1AX-B\,^"/V(?#VM:3J,D6GR%;K3 M;J*%92AS_<#R<\]<8]!R>F/89SU]^E!3)SGTXZ=,=Q_G\*=SS[G\A[?AS]<] MJ^PXNXUS/C+#<)87,L+@<-2X-X5P?".6_4J';VUC\>G5[#4M7TU9/#OQOT:>/5KV6#S8[GQ7=>-I=12#[=!)=?VF_"G MQ?K/Q ^&O@7QKXA\&>(/AQK_ (I\*:+K>O> ?%EO':^(O!FM7]A!/JOAK5X( MI)XA=Z/?M<64DL,TL%PD27$,C12H3Z"1W&.F #TZ@]OI2X_SWY.3_2M.*..L MXXORCA3*LZI8/$5.#\M>39;FZIU%FN)RI3C+#8',*\IN.)HX%1A'!^ZI48QD MHRM4G$C"9=A\#4Q=3#NI&.,K/$5*3DG2C6DK2E2C9."E;WHIM2;\DS^4W_@Y MW_8._:[_ &W= _8\L_V5/@9XC^-'];\%Z,= LO$.B^$K71 MI+EO%WB;PZ+G^T9M/O8X4T_[4Z&!C/Y*E"WX]^ /AQ_P=A_"WP;X3^&_P_\ M#/[0?AGP+X'T'3_#/A70+/7/V6Y;72-#TFW6UT[38'O->NKN6&U@1(DFN;R: M=D50[O@8_P!#;'7//.1[Y[G\>O_UJ^^X6\=5C MN&J&,QU7,(9AFF!Q%>BJ-9X'$JC"<(I*-TX-WCJXN[LVWH['\!ND6O\ P=R_ MV[H7]HVW[1']DG6])_M4R:M^RGM&F?;X/MV]8=8+F+[)YWG>7B78/W0,A3/] M[NA"_P#[#T?^U-XU4Z3IPU+S/+\S^T!:1?;/,,68B_VCS YB^3<#L.W%:N!Z M#.?3WY_'^M XS]3C\>?YY_"OB^.^.X\TJ595ZE*46J,V[QA)PNTD>CEF6O+83I_7L?CN?EM/'UE7G'ENO=E MRQW32=UKRJ]W=O\ BR_X.*_V#/VS/VG_ /@H7^S!\3OV>OV)O%W@_3[&\TC1M>T_X\_$'Q'J&DWS7&H6TR75GH6HZ?JMQB Q):7D# M"5F9D7^TB %(848_,D4:,/\ :"(#UP>OJ >>G-2D=.!^/]/QQ1@9S[8_7/YU MYV?<99IQ#P]P7PUC:&#IX'@7+\QRW*:V'IU(XG$8?,L?4S&L\=*S5DXQ<(KF3U78_,'_ (*I_P#!,SX6?\%,OV>+[X<^(A8^%OC#X+6_\0? ?XMFR6;4? WC M!X$+Z9J;1@76I> O%OV6VT[QGX>W>5=6L5IJUJL6M:/I5U!_,;_P0?\ ^";' M[=_[*'_!3BP\;_M"_LT^//A[X$\._#+XR^"]0^(&>*,-4H5\)CHUJE3+*M>5-U\3 ME=2G5C[&=9TH.I1J0>'E-SJJ$9SGS<>+X?R_&9G@\WG&=/'8*HIQJTG&*K** ME&,*\'%J:2EI-.-31*[25C! /KD$GCGGTQ_= ']<\U_-A_P57_X-[/AY^VCX MLUS]H+]F7Q9H/P(_:,UN9=3\6:3K]A>-\)/BGJ\*J$U?6SH-M'Q>%J-.M@L=A9OV&+P==+EJT*RY6M82IR=WWX_+\)F6'EA ML9156FVG%W<:E.:T52E42G]E:!=Z)XH^"'[1/AE=*LRUK9_\(U>>-+OQ%XC\*:2(T_T.PU72?"5W M%$$EETZVW+6IX;_X(N?\%EO^"B7C_1?%/_!0#XM:G\+?!EA<12OK'Q9^(6B? M$OQI::7<2>9%[M\R>9%XDUKP?':2L9FTK5 S0O\ W>;0 M/<@$#/3KD9H*YQT[=N@'I^OX'%?JU7Z0O$%.,\3D_ WAAP]GU957B.)%'A/"&VTG0].BM]*T> MRL[&W2(?7U%%?AV.Q^.S3&XK,LSQ>(Q^88ZO/$XS&8NK.OB<37J.\ZM:K-N4 MY-V2V48QC"$80C"*^FI4J5"G"C1IPI4J48PITZ<5"$(Q5E&,8I))>2];N[:$ M9&/_ *U?AMX6_P""3VG>'/\ @L5XJ_;O&FZ4WPKU+X=_\)IX?TQ&LQ+IO[0V MJ%?"_B:\;3HGAFB@GT".'Q+I]X+&5/[9O-7DDO1EDO$N=\.1SB.2XZK@EGV2XSA_-53O_ +3E>.E2EB*.DX!PN-^K_6:2J_5<32Q="_V*]%R<);.ZO+WHNT96C?X4,52#SCYE MYQGMC/IZ_7CK3L<<#TQG(^Z>,\''Y9-+CG/X'Z?_ *Z6O!44E9+3IMIM;2RT M5E%+HDNQU_-OU_K^KGYL?\%&?^"8OP+_ ."BW@72]-\<37?@'XM>#(;D?#3X MU>&]/M+WQ%X86Y\':@S-(+: MYOO@U\7);#4M(U9H5+7,&G>'O$FF6#NUM'XAU!7$LO\ ;Z5SWYYY.#V(].P) MX&.I]:;L& <8XX[C&/7KCJ>_>OU/A'Q>XIX4RF'#=;"Y'Q;PG3KRQ-+A?C' M+%G64X.M.:G7GEG-7H8G*IXEK][+!5%'F(/V2_P#@X*_;T%KX*^.N MI^,O"GPXU*3[-K^ ?A1\/$6*6.02:]\/OA/%/XH\08B:T6=U5;R^N[V^US5TC07-W;VK26-?K=M'ITQ^ M8SS^-* 0,<9_(9_"M>*_&3BKB;*J_#F#P/#_ ;POBIPJ8KA[@S*HY-@,9.G M9Q_M"JJU7&8Y72-JSQ688ZE%QIXW,<1+% M5J:=[NDG&%*E)W:O"FG&\N7E$/^Q'U?_P!.&H5^K%I_QZ6O_7O#_P"BUK\X/VX?AC\1O'?B;PQ=>"O! M.O\ BFVM/"&IV=S/H]M#/'!=RWM[)%;2&6XA(E=)$=0 1M8I>"O&.GV%N]S?7_A?Q%9V5O&5\RYNKS2+N"W@C#LJ[Y9I(XU+ MLBAFPS*,FOYF/^""'[''[4O[-?QA^*^O_'SX'^-/A3H^M_ WPUH&DWWBA-*6 M&]UN'Q%H5]-?#3P4Z_#S7/B3H4>EWFAZEX(,BZM\,OB;)9'5SJ,&J^&X;VUTWQ=I]M9W]Q M9W#>+K6U-X)K:Y;^J@@Y!!Z=1ZC_ #THP,Y[^M'#7'&:<,Y'Q;P[1PF S+)^ M,LOPV!S/!YC3JS^KU,'B5B<-F.7U*4HSPN/I->R]LN>,Z*@I14H*3>-RREC, M3@,6ZM>A7R^K.K2G0G&*J1J0Y)T:\91:J47\:C=6G>2=]#C/B'XHO_!/@7Q? MXOTGPGKWCO5O#?AS5M8TCP3X6@6X\1>+M5L+*:XT[PUHJ28ACO\ 6[U8--M[ MJ[:*PLVN/M>H3064$\T?\SW_ 3?_8,_:>^)W[."IXCB_ 8?* ML=GL_K#S; Y72K2K8C Y7.%2G1PT,PE.<,;4:G5JTG&FN6,(DXS*L/C\7E^+ MQ,JLO[-J3KX?#J450=>O6VBR7$\5DEVLOD_\ P1G/[5'@/X"ZC^SW^TY\&OB'\.T^%-XTGPG\2>+[ M6Q6SU7P)KU[>7;>#H[FUO+F87/@K56NH=(AN@,>%M0TJQM?(M=(BM8OV/P/K M]: ,=.G_ .K']?QIPXZS7_4&?AUB,+E^-R6/$$.),NQ6(I57F>38_P"K/"XB MEEV)C4Y*6"QL&IXO"SI EX-101.SCH 4 rnxt-20231114.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 rnxt-20231114_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 6 rnxt-20231114_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 14, 2023
Entity File Number 001-40738
Entity Registrant Name RENOVORX, INC.
Entity Central Index Key 0001574094
Entity Tax Identification Number 27-1448452
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4546 El Camino Real
Entity Address, Address Line Two Suite B1
Entity Address, City or Town Los Altos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94022
City Area Code (650)
Local Phone Number 284-4433
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol RNXT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001574094 2023-11-14 2023-11-14 iso4217:USD shares iso4217:USD shares false 0001574094 8-K 2023-11-14 RENOVORX, INC. DE 001-40738 27-1448452 4546 El Camino Real Suite B1 Los Altos CA 94022 (650) 284-4433 Not Applicable false false false false Common Stock, $0.0001 par value per share RNXT NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://renovorx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm rnxt-20231114.xsd rnxt-20231114_lab.xml rnxt-20231114_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "RNXT", "nsuri": "http://renovorx.com/20231114", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "rnxt-20231114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rnxt-20231114_lab.xml" ] }, "presentationLink": { "local": [ "rnxt-20231114_pre.xml" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 60, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://renovorx.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://renovorx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-040786-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040786-xbrl.zip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